Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including the Russell 2000 Value Index, expanding its presence in key equity indices.

Recursion Pharmaceuticals has been trying to rebuild momentum after a steep five year decline in shareholder returns, yet its ...

The US AI research company Anthropic has become known for building powerful AI models while simultaneously warning about ...

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

Google is expected to launch Gemini 3.5 Pro on July 17 with a rumored 2M-token context window and 'Deep Think' reasoning.

Learn more about whether Recursion Pharmaceuticals, Inc. or Syndax Pharmaceuticals, Inc. is a better investment based on AAII ...

An updated edition of the May 18, 2026, article. The global oncology market is evolving rapidly, fueled by rising cancer incidence, an aging population and continued scientific innovation. According ...

Gemini 3.5 Pro release targets July 17, 2026 — four days away — but Google has not confirmed the date, the 2-million-token ...

What if the same Bitcoin signature could authorize spending from multiple different UTXOs? BIP 118's ANYPREVOUT does exactly ...

Google DeepMind's Gemini 3.5 Pro has now missed its launch target three consecutive times — June, then July 17, and now beyond — with Geeky Gadgets reporting Wednesday that the rebuilt model is still ...

Press’ post set off a firestorm of controversy within the Haskell community, which is small but vocal, and likely felt the ...